Press Release

June 30, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai- 400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Commencement of Commercial Production Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company has inaugurated and successfully commenced the commercial production at its EU-GMP approved Women’s Hormone manufacturing facility at Bhayla, Ahmedabad. The Press Release in the matter is enclosed herewith. This intimation is also being made available on the website of the Company at www.coronaremedies.com You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a PRESS RELEASE CORONA Remedies commercialises India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility Ahmedabad, June 30, 2026: Reinforcing its long-term commitment to advancing women's healthcare, CORONA Remedies Limited today announced the inaugura(cid:415)on and commercialisa(cid:415)on of its dedicated EU-GMP approved Hormone Manufacturing Facility at Bhayla, Ahmedabad. The facility marks a significant milestone in the Company's journey towards building globally benchmarked pharmaceu(cid:415)cal manufacturing capabili(cid:415)es. The state-of-the-art facility was inaugurated by Chairman, Dr. K. L. Mehta, alongside long- serving women employees of the organisa(cid:415)on—symbolising CORONA's enduring commitment to women's health and the invaluable contribu(cid:415)on of women in shaping the Company's success. Responding to the Growing Need for Women's Healthcare As global a(cid:425)en(cid:415)on towards women's healthcare con(cid:415)nues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fer(cid:415)lity care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceu(cid:415)cal manufacturing has become more cri(cid:415)cal than ever (as per WHO factsheet on Infer(cid:415)lity Nov. 2025). As therapies become increasingly specialised, manufacturing excellence has emerged as a cri(cid:415)cal pillar alongside clinical innova(cid:415)on. Hormonal medicines are among the most complex pharmaceu(cid:415)cal products to manufacture. Their high potency, sensi(cid:415)ve formula(cid:415)ons and stringent contamina(cid:415)on control requirements demand dedicated facili(cid:415)es equipped with sophis(cid:415)cated technologies, specialised engineering systems and uncompromising regulatory standards. Recognising this evolving need, CORONA Remedies has established one of India's most advanced dedicated hormone manufacturing facili(cid:415)es, strengthening its capabili(cid:415)es to serve both domes(cid:415)c and interna(cid:415)onal markets. A Purpose-Built Manufacturing Ecosystem Unlike conven(cid:415)onal pharmaceu(cid:415)cal manufacturing plants, dedicated hormone manufacturing requires complete segrega(cid:415)on of opera(cid:415)ons, precision environmental controls, specialised containment technologies and highly trained personnel to ensure safe handling of potent hormone ac(cid:415)ve pharmaceu(cid:415)cal ingredients (APIs). CORONA's integrated manufacturing pla(cid:414)orm supports mul(cid:415)ple dosage forms—including tablets, so(cid:332) gel capsules, ointments and gels—within a single specialised manufacturing ecosystem, enabling the Company to cater to a broad spectrum of women's healthcare therapies. Spread across 1.0 lakh sq. (cid:332); the facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. With the commissioning of this facility, CORONA's in-house hormone manufacturing capacity is expected to increase by nearly 20%. Advanced Manufacturing Technologies The facility incorporates next-genera(cid:415)on manufacturing technologies and digital process controls to ensure product consistency, precision and opera(cid:415)onal excellence. Key capabili(cid:415)es include:  Fully integrated closed-loop manufacturing systems supported by 21 CFR-compliant equipment and Quality by Design (QbD) principles.  Advanced gela(cid:415)n processing systems with precision-controlled agita(cid:415)on and jacketed vessels for accurate temperature management, superior uniformity and formula(cid:415)on consistency.  Real-(cid:415)me online process monitoring for enhanced batch-to-batch reproducibility and product quality. Leadership Perspec(cid:415)ve Speaking on the occasion, Mr. Nirav K. Mehta, Founder, Managing Director & CEO, CORONA Remedies Limited said: "Women's healthcare con(cid:415)nues to be one of the fastest evolving areas of modern medicine. At CORONA, we believe scien(cid:415)fic innova(cid:415)on must be complemented by world-class manufacturing capabili(cid:415)es. This dedicated hormone facility represents our commitment to delivering globally benchmarked quality, strengthening India's pharmaceu(cid:415)cal manufacturing ecosystem and ensuring women have access to safe, reliable and high-quality hormone therapies." About CORONA Remedies Limited Founded in 2004, CORONA Remedies Limited is the India’s fastest growing pharmaceu(cid:415)cal companies amongst Top 30 Pharmaceu(cid:415)cal corporates, engaged in developing, manufacturing, and marke(cid:415)ng products across key therapeu(cid:415)c areas including women’s healthcare, cardio-diabetes, pain management, and urology. The Company operates WHO GMP / EU GMP-cer(cid:415)fied manufacturing facili(cid:415)es and maintains strong innova(cid:415)on capabili(cid:415)es through DSIR-approved R&D centres. Safe Harbour Statement: Certain statements contained in this document may be statements of future expecta(cid:415)ons and other forward-looking statements that are based on management‘s current view and assump(cid:415)ons and involve known and unknown risks and uncertain(cid:415)es that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representa(cid:415)ves shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connec(cid:415)on with this document. This document does not cons(cid:415)tute an offer or invita(cid:415)on to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connec(cid:415)on with any contract or commitment whatsoever. For further details please contact: Company Investor Rela(cid:415)ons Advisors CORONA Remedies Limited Strategic Growth Advisors Pvt Ltd. CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Mr. Sagar Shroff / Mr. Tanay Shah Compliance Officer Email Id: sagar.shroff@sgapl.net / Email Id: investor@coronaremedies.com tanay.shah@sgapl.net Tel. No.: +91 98205 19303 / +91 98333 91899